Axsome Therapeutics, Inc. (0HKF.L)
USD 101.16
(-6.16%)
USD 101.16
(-6.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -199.82 Million USD | -88.23% |
| 2022 | -106.15 Million USD | -188.77% |
| 2021 | -36.76 Million USD | 72.51% |
| 2020 | -133.75 Million USD | 33.13% |
| 2019 | -200.03 Million USD | -2734.14% |
| 2018 | -7.05 Million USD | 70.7% |
| 2017 | -24.08 Million USD | 10.38% |
| 2016 | -26.87 Million USD | 44.04% |
| 2015 | -48.03 Million USD | -2675.58% |
| 2014 | 1.86 Million USD | 7.32% |
| 2013 | 1.73 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -123.85 Million USD | 12.78% |
| 2024 Q1 | -142.01 Million USD | 28.93% |
| 2023 Q2 | -252.4 Million USD | -155.49% |
| 2023 Q1 | -98.79 Million USD | 6.94% |
| 2023 FY | -199.82 Million USD | -88.23% |
| 2023 Q4 | -199.82 Million USD | 13.49% |
| 2023 Q3 | -230.98 Million USD | 8.48% |
| 2022 Q2 | 20.77 Million USD | 160.34% |
| 2022 Q4 | -106.15 Million USD | 20.3% |
| 2022 Q1 | -34.42 Million USD | 6.35% |
| 2022 FY | -106.15 Million USD | -188.77% |
| 2022 Q3 | -133.19 Million USD | -741.16% |
| 2021 Q2 | -91.16 Million USD | 20.4% |
| 2021 Q4 | -36.76 Million USD | 43.06% |
| 2021 FY | -36.76 Million USD | 72.51% |
| 2021 Q3 | -64.56 Million USD | 29.17% |
| 2021 Q1 | -114.53 Million USD | 14.37% |
| 2020 FY | -133.75 Million USD | 33.13% |
| 2020 Q1 | -177.2 Million USD | 11.41% |
| 2020 Q2 | -170.39 Million USD | 3.84% |
| 2020 Q3 | -154.33 Million USD | 9.42% |
| 2020 Q4 | -133.75 Million USD | 13.34% |
| 2019 Q3 | -23.88 Million USD | 30.11% |
| 2019 Q1 | -23.27 Million USD | -229.72% |
| 2019 FY | -200.03 Million USD | -2734.14% |
| 2019 Q2 | -34.17 Million USD | -46.85% |
| 2019 Q4 | -200.03 Million USD | -737.47% |
| 2018 Q3 | -7.49 Million USD | 36.92% |
| 2018 Q1 | -17.42 Million USD | 27.66% |
| 2018 FY | -7.05 Million USD | 70.7% |
| 2018 Q4 | -7.05 Million USD | 5.83% |
| 2018 Q2 | -11.88 Million USD | 31.82% |
| 2017 Q1 | -35.16 Million USD | -30.83% |
| 2017 FY | -24.08 Million USD | 10.38% |
| 2017 Q4 | -24.08 Million USD | -11.62% |
| 2017 Q3 | -21.58 Million USD | 22.98% |
| 2017 Q2 | -28.02 Million USD | 20.31% |
| 2016 Q1 | -44.07 Million USD | 8.24% |
| 2016 FY | -26.87 Million USD | 44.04% |
| 2016 Q4 | -26.87 Million USD | 20.68% |
| 2016 Q3 | -33.88 Million USD | 12.55% |
| 2016 Q2 | -38.75 Million USD | 12.08% |
| 2015 FY | -48.03 Million USD | -2675.58% |
| 2015 Q2 | 4.49 Million USD | 71.69% |
| 2015 Q4 | -48.03 Million USD | -556.75% |
| 2015 Q3 | 10.51 Million USD | 133.99% |
| 2015 Q1 | 2.61 Million USD | 40.36% |
| 2014 FY | 1.86 Million USD | 7.32% |
| 2014 Q4 | 1.86 Million USD | 0.0% |
| 2014 Q1 | 2.08 Million USD | 0.0% |
| 2013 FY | 1.73 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -94.093% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -540.103% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 200.887% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 726.693% |
| bluebird bio, Inc. | 108.57 Million USD | 284.046% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -2116.293% |
| Imunon, Inc. | -4.69 Million USD | -4152.168% |
| Editas Medicine, Inc. | -87.11 Million USD | -129.373% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 101.554% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 109.525% |
| Myriad Genetics, Inc. | 88.1 Million USD | 326.812% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 212.702% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -496.0% |
| Verastem, Inc. | -37.27 Million USD | -436.029% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 102.426% |
| Waters Corporation | 1.96 Billion USD | 110.193% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.744% |
| Biogen Inc. | 6.28 Billion USD | 103.178% |
| Nektar Therapeutics | 210.24 Million USD | 195.044% |
| Perrigo Company plc | 3.32 Billion USD | 106.015% |
| Dynavax Technologies Corporation | 106.63 Million USD | 287.388% |
| Illumina, Inc. | 1.21 Billion USD | 116.46% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 2967.664% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -75.454% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 237.735% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 2880.312% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 152.758% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -2714.38% |
| Evolus, Inc. | 63.7 Million USD | 413.651% |
| Adicet Bio, Inc. | -142 Million USD | -40.711% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -442.933% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -637.347% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 143.563% |
| FibroGen, Inc. | 56.76 Million USD | 452.002% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 117.452% |
| OPKO Health, Inc. | 230.68 Million USD | 186.621% |
| Homology Medicines, Inc. | 18.43 Million USD | 1183.804% |
| Geron Corporation | 14.76 Million USD | 1453.709% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 112.604% |
| Exelixis, Inc. | -73.05 Million USD | -173.54% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -268.293% |
| Anavex Life Sciences Corp. | -151.02 Million USD | -32.311% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -79.369% |
| Zoetis Inc. | 4.76 Billion USD | 104.196% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1884.123% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 97.911% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -1271.267% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 118.953% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 120.635% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | -47.578% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 114.471% |
| Blueprint Medicines Corporation | 702.83 Million USD | 128.431% |
| Insmed Incorporated | 721.62 Million USD | 127.691% |
| TG Therapeutics, Inc. | 17.86 Million USD | 1218.693% |
| Incyte Corporation | -3.17 Billion USD | 93.707% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 126.093% |